Donnerstag, 6. Februar 2020

Hans van Schijndel appointed as Chief Research & Development Officer of HAL Allergy Holding B.V.

 

HAL Allergy announces that the Supervisory Board has appointed Dr. Hans van Schijndel as Member of the Board of HAL Allergy Holding B.V. in the position of Chief Research & Development Officer (Chief R&D Officer) as of 1 February 2020.

 
With this appointment, the Board of Directors is now complete. Next to Dr. Hans van Schijndel, in charge of the R&D program, the Board consists of Florian Rösch being the Chief Commercial & Financial Officer and Dr. Eize de Boer, the Chief Operations Officer taking care of Production and Quality Assurance.
 
Dr. Hans van Schijndel has a PhD in Biochemistry and is employed by HAL Allergy since 2012. In his career at HAL Allergy he served as Principal Scientist/Head of Pre-clinical Research and was engaged in several bio-technological projects including the Therapieallergene-Verordnung (TAV) program. In his position of Chief R&D Officer he will take care of this TAV-Program and significant novel developments in the food and inhalative sector including clinical development to enable the treatment of Peanut and Ragweed allergies.
 
HAL Allergy specializes in immunotherapy, desensitization and therapeutic treatment of all allergies mainly caused by tree and grass pollens and mites with the help of preparations that can be administered sublingually or subcutaneously. The company works intensively in collaboration with its sales organizations, distributors and internationally acclaimed research institutes to bring out the best possible combination of knowledge and experience.
 
As Chief Technology Officer, Dr. Hans van Schijndel also joins the Board of Directors of HALIX B.V.
As of the 1 February the composition of the Board is as follows: Alex Huybens, Chief Operations Officer, Florian Rösch, Chief Financial Officer and Dr. Hans van Schijndel, Chief Technology Officer.
 
HALIX is a corporate venture and spin-off of HAL Allergy, serving customers as a contract development and manufacturing organization (CDMO). HALIX leverages advanced biopharmaceutical technologies and provides its customers the full range from the first development steps to start of commercial production after successful registration of products.

zurück nach oben
News Aus der Gruppe
schliessen